Generic manufacturers cease production of Purdue’s OxyContin
STAMFORD, Conn. As of Feb. 1, 2008, Teva, Impax Laboratories and Dava Pharmaceuticals have discontinued their distribution and sales of generic versions of Purdue Pharma’s narcotic pain medication OxyContin (called oxycodone hydrogen chloride controlled-release).
On Dec. 31, 2006, Endo Pharmaceuticals also ceased distribution of its generic version of OxyContin. All instances of discontinuation came in relation to the respective companies’ licenses with Purdue.
The licenses granted to Teva, Impax and Endo Pharmaceuticals preceded a decision on Jan. 7, 2008, by the U.S. District Court for the Southern District of New York in which the court ruled that Purdue Pharma had not committed unfair conduct in obtaining its OxyContin patents and that its patents are not unenforceable for that reason.
Purdue will continue to sell and distribute OxyContin Tablets and expects to be able to meet all demand for long-acting oxycodone prescriptions. The last of Purdue’s patents on OxyContin tablets expire in April 2013.
Parata launches PACMED C30 packaging technology
DURHAM, N.C. Parata Systems has launched its new product, the PACMED C30, which is a packaging technology used to extend the safety and convenience of its onePAC packaging system.
onePac is a strip that contains information like patients’ medications, patient names, pill descriptions and time of day to take a dose of the medication. On the strip, up to 19 lines of information can be held. The goal of the strips are to remind patients who take multiple medications when to take what medications and how much of each medication.
The PACMED C30 expands on the technology of the onePAC by combining multiple onePAC strips together for easy access by patients. PACMED C30 is efficient and accurate, generating up to 60 unit-dose or 50 multi-dose packages a minute.
“Adherence is a critical touch point in the circle of pharmacy care, and Parata’s launch of PACMED C30 offers an exciting new way for pharmacies to extend their care by improving patient adherence, safety and convenience,” says Tom Rhoads, executive vice president for customer and market strategies at Parata Systems.
Teva announces availablility of generic Fosamax
NORTH WALES, Pa. Teva has announced the introduction and availability of alendronate sodium tablets.
This is the generic version of the osteoporosis drug Fosamax by Merck. The drug will be available in 5 mg, 10 mg, 35 mg, 40 mg and 70 mg strengths.
“Our customers count on Teva for a continuous supply of new generic products,” stated John Denman, vice president of sales and marketing. “With the launch of alendronate sodium tablets, we add another quality product to our broad line of affordable generic pharmaceuticals.”